A proposal is presented to utilize tracers labeled with positron emitters and positron emission transaxial tomographs (PETT) to carry out mapping of static and dynamic functions of the brain. An immediate application will involve the use of 18F-2-deoxy-2-fluoro-D-glucose (FDG) for measuring regional glucose metabolism in a variety of normal and pathological states in the baboon and human brain. In addition, this technique, pioneered by the University of Pennsylvania in collaboration with BNL, will be applied to determining sites of action in the brain related to specific drug intervention. A new aspect of the application of this combination of research tools will be to develop useful labeled agonists and antagonists and other psychotropic agents and apply them to basic studies on opiate, dopaminergic, and other receptor action. Thus, for the first time it may be possible to probe ligand-receptor interrelations in the intact brain in a non-invasive and quantitative way. Other applications will involve studies in anesthesia, enzyme mapping, and on the functional architecture of the human visual cortex. Studies to determine the relation between glucose metabolism and pathological state involve both the investigaion of fundamental relationships and also effectiveness of treatment as mirrored in metabolic activity. Twelve studies are proposed ranging from those on animals alone to research with human subjects involving both basic and clinical aspects. The clinical studies include the development of heretofore inaccessible information on aging, schizophrenia, and the relation of drug therapy to these states. Other clinical studies will use these techniques to study rCGM and rCBF before and after drug or surgical intervention, in treating patients with patent disease with the goal of improving diagnosis and therapy. The majority of these studies require as an essential aspect the improved spatial resolution of the newer PETT machines in order to be effective. Thus, the proposal includes a request for such a machine plus a request for modest cyclotron improvement in order to afford efficient realization of this project.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
5P01NS015638-08
Application #
3099538
Study Section
(SRC)
Project Start
1979-09-01
Project End
1989-08-31
Budget Start
1986-09-01
Budget End
1987-08-31
Support Year
8
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Associated University-Brookhaven National Lab
Department
Type
DUNS #
City
Upton
State
NY
Country
United States
Zip Code
11973
Fowler, J S; Volkow, N D; Logan, J et al. (1998) Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. Synapse 28:111-6
Marcus, D L; Strafaci, J A; Miller, D C et al. (1998) Quantitative neuronal c-fos and c-jun expression in Alzheimer's disease. Neurobiol Aging 19:393-400
Schlosser, R; Brodie, J D; Dewey, S L et al. (1998) Long-term stability of neurotransmitter activity investigated with 11C-raclopride PET. Synapse 28:66-70
Fowler, J S; Volkow, N D; Wang, G J et al. (1998) Visualization of monoamine oxidase in human brain. Adv Pharmacol 42:304-7
Smith, G S; Schloesser, R; Brodie, J D et al. (1998) Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 18:18-25
Bartlett, E J; Brodie, J D; Simkowitz, P et al. (1998) Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am J Psychiatry 155:337-43
Shiue, C Y; Vallabhahosula, S; Wolf, A P et al. (1997) Carbon-11 labelled ketamine-synthesis, distribution in mice and PET studies in baboons. Nucl Med Biol 24:145-50
Smith, G S; Dewey, S L; Brodie, J D et al. (1997) Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects. Am J Psychiatry 154:490-6
Ding, Y S; Fowler, J S; Volkow, N D et al. (1997) Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl) 131:71-8
Marcus, D L; Freedman, M L (1997) Decreased brain glucose metabolism in microvessels from patients with Alzheimer's disease. Ann N Y Acad Sci 826:248-53

Showing the most recent 10 out of 111 publications